Erlotinib Hydrochloride

盐酸厄洛替尼

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameErlotinib Hydrochloride
Drug Alias NameErlotinibum埃罗替尼盐酸盐erlotinib盐酸埃罗替尼厄洛替尼 +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR 19del inhibitorsEGFR L858R inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1EGFR 19delEGFR L858R
Therapy Area/IndicationsBrain metastasesEsophageal adenocarcinomaMetastatic breast cancer +[106] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2004/11/18
Country/TerritoryCzechiaBelgiumBulgaria +[55] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesSchwarz Pharma Manufacturing IncUniversity of Texas Southwestern Medical CenterQingdao Landgo Pharmaceutical Co Ltd +[14] 
Inactive CompaniesMedicallogicUtah State UniversityDana-Farber Cancer Institute +[39] 
Active IndicationsSolid tumoursKeratoderma, PalmoplantarHyperkeratosis, Epidermolytic +[15] 
Inactive IndicationsBrain metastasesEsophageal adenocarcinomaMetastatic breast cancer +[91] 

Other Information

ATC CodeL01EB02
Related LinksWikipediaDrugBankKEGG